1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for
Study
1.2.3. Key Market Segmentations
2.
Research Methodology
2.1.
Objective of
the Study
2.2.
Baseline
Methodology
2.3.
Key Industry
Partners
2.4.
Major
Association and Secondary Sources
2.5.
Forecasting
Methodology
2.6.
Data
Triangulation & Validation
2.7.
Assumptions
and Limitations
3.
Executive Summary
3.1. Overview of the
Market
3.2. Overview of Key
Market Segmentations
3.3. Overview of Key
Market Players
3.4. Overview of Key
Regions/Countries
3.5. Overview of Market
Drivers, Challenges, Trends
4. Global Hereditary
Angioedema Therapeutics Market Outlook
4.1.
Market Size & Forecast
4.1.1. By Value
4.2.
Market Share & Forecast
4.2.1.
By Drug Class (C1 Esterase Inhibitor, Selective
Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes)
4.2.2. By Distribution Channel (Hospital
Pharmacy, Retail Pharmacy, Other Distribution Channels)
4.2.3.
By Application (Prophylaxis, On-demand)
4.2.4.
By Region
4.2.5. By Company (2022)
4.3.
Market Map
4.3.1. By Drug Class
4.3.2. By Distribution
Channel
4.3.3. By Application
4.3.4. By Region
5. Asia Pacific
Hereditary Angioedema Therapeutics Market Outlook
5.1.
Market Size & Forecast
5.1.1. By Value
5.2.
Market Share & Forecast
5.2.1.
By Drug Class
5.2.2. By Distribution
Channel
5.2.3.
By Application
5.2.4. By Country
5.3.
Asia Pacific: Country Analysis
5.3.1. China Hereditary
Angioedema Therapeutics Market Outlook
5.3.1.1.
Market Size & Forecast
5.3.1.1.1.
By Value
5.3.1.2.
Market Share & Forecast
5.3.1.2.1.
By Drug Class
5.3.1.2.2.
By Distribution Channel
5.3.1.2.3.
By Application
5.3.2. India Hereditary
Angioedema Therapeutics Market Outlook
5.3.2.1.
Market Size & Forecast
5.3.2.1.1.
By Value
5.3.2.2.
Market Share & Forecast
5.3.2.2.1.
By Drug Class
5.3.2.2.2.
By Distribution Channel
5.3.2.2.3.
By Application
5.3.3. Australia Hereditary
Angioedema Therapeutics Market Outlook
5.3.3.1.
Market Size & Forecast
5.3.3.1.1.
By Value
5.3.3.2.
Market Share & Forecast
5.3.3.2.1.
By Drug Class
5.3.3.2.2.
By Distribution Channel
5.3.3.2.3.
By Application
5.3.4. Japan Hereditary
Angioedema Therapeutics Market Outlook
5.3.4.1.
Market Size & Forecast
5.3.4.1.1.
By Value
5.3.4.2.
Market Share & Forecast
5.3.4.2.1.
By Drug Class
5.3.4.2.2.
By Distribution Channel
5.3.4.2.3.
By Application
5.3.5. South Korea
Hereditary Angioedema Therapeutics Market Outlook
5.3.5.1.
Market Size & Forecast
5.3.5.1.1.
By Value
5.3.5.2.
Market Share & Forecast
5.3.5.2.1.
By Drug Class
5.3.5.2.2.
By Distribution Channel
5.3.5.2.3.
By Application
6. Europe Hereditary
Angioedema Therapeutics Market Outlook
6.1.
Market Size & Forecast
6.1.1. By Value
6.2.
Market Share & Forecast
6.2.1. By
Drug Class
6.2.2. By Distribution
Channel
6.2.3. By
Application
6.2.4. By
Country
6.3.
Europe: Country Analysis
6.3.1. France Hereditary
Angioedema Therapeutics Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Drug Class
6.3.1.2.2.
By Distribution Channel
6.3.1.2.3.
By Application
6.3.2. Germany Hereditary
Angioedema Therapeutics Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Drug Class
6.3.2.2.2.
By Distribution Channel
6.3.2.2.3.
By Application
6.3.3. Spain Hereditary
Angioedema Therapeutics Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Drug Class
6.3.3.2.2.
By Distribution Channel
6.3.3.2.3.
By Application
6.3.4. Italy Hereditary Angioedema
Therapeutics Market Outlook
6.3.4.1.
Market Size & Forecast
6.3.4.1.1.
By Value
6.3.4.2.
Market Share & Forecast
6.3.4.2.1.
By Drug Class
6.3.4.2.2.
By Distribution Channel
6.3.4.2.3.
By Application
6.3.5. United Kingdom
Hereditary Angioedema Therapeutics Market Outlook
6.3.5.1.
Market Size & Forecast
6.3.5.1.1.
By Value
6.3.5.2.
Market Share & Forecast
6.3.5.2.1.
By Drug Class
6.3.5.2.2.
By Distribution Channel
6.3.5.2.3.
By Application
7. North America
Hereditary Angioedema Therapeutics Market Outlook
7.1.
Market Size & Forecast
7.1.1. By Value
7.2.
Market Share & Forecast
7.2.1. By
Drug Class
7.2.2. By
Distribution Channel
7.2.3. By Application
7.2.4. By Country
7.3.
North America: Country Analysis
7.3.1. United States
Hereditary Angioedema Therapeutics Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Drug Class
7.3.1.2.2.
By Distribution Channel
7.3.1.2.3.
By Application
7.3.2. Mexico Hereditary
Angioedema Therapeutics Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Drug Class
7.3.2.2.2.
By Distribution Channel
7.3.2.2.3.
By Application
7.3.3. Canada Hereditary
Angioedema Therapeutics Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Drug Class
7.3.3.2.2.
By Distribution Channel
7.3.3.2.3.
By Application
8. South America
Hereditary Angioedema Therapeutics Market Outlook
8.1.
Market Size & Forecast
8.1.1. By Value
8.2.
Market Share & Forecast
8.2.1. By
Drug Class
8.2.2.
By Distribution Channel
8.2.3.
By Application
8.2.4. By Country
8.3.
South America: Country Analysis
8.3.1. Brazil Hereditary
Angioedema Therapeutics Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Drug Class
8.3.1.2.2.
By Distribution Channel
8.3.1.2.3.
By Application
8.3.2. Argentina Hereditary
Angioedema Therapeutics Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Drug Class
8.3.2.2.2.
By Distribution Channel
8.3.2.2.3.
By Application
8.3.3. Colombia Hereditary
Angioedema Therapeutics Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Drug Class
8.3.3.2.2.
By Distribution Channel
8.3.3.2.3.
By Application
9. Middle East and
Africa Hereditary Angioedema Therapeutics Market Outlook
9.1.
Market Size & Forecast
9.1.1. By Value
9.2.
Market Share & Forecast
9.2.1. By
Drug Class
9.2.2. By Distribution
Channel
9.2.3. By
Application
9.2.4. By Country
9.3.
MEA: Country Analysis
9.3.1. South Africa
Hereditary Angioedema Therapeutics Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Drug Class
9.3.1.2.2.
By Distribution Channel
9.3.1.2.3.
By Application
9.3.2. Saudi Arabia
Hereditary Angioedema Therapeutics Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Drug Class
9.3.2.2.2.
By Distribution Channel
9.3.2.2.3.
By Application
9.3.3. UAE Hereditary
Angioedema Therapeutics Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Drug Class
9.3.3.2.2.
By Distribution Channel
9.3.3.2.3.
By Application
9.3.4. Egypt Hereditary
Angioedema Therapeutics Market Outlook
9.3.4.1.
Market Size & Forecast
9.3.4.1.1.
By Value
9.3.4.2.
Market Share & Forecast
9.3.4.2.1.
By Drug Class
9.3.4.2.2.
By Distribution Channel
9.3.4.2.3.
By Application
10.
Market Dynamics
10.1.
Drivers
10.2.
Challenges
11.
Market Trends & Developments
11.1.
Recent Developments
11.2.
Product Launches
11.3.
Mergers & Acquisitions
12.
Global Hereditary Angioedema Therapeutics Market: SWOT
Analysis
13. Porter’s Five Forces
Analysis
13.1.
Competition in the Industry
13.2.
Potential of New Entrants
13.3.
Power of Suppliers
13.4.
Power of Customers
13.5.
Threat of Substitute Product
14.
Competitive Landscape
14.1. Shire plc
14.1.1.
Business Overview
14.1.2.
Company Snapshot
14.1.3.
Products & Services
14.1.4.
Current Capacity Analysis
14.1.5.
Financials (In case of listed)
14.1.6.
Recent Developments
14.1.7.
SWOT Analysis
14.2. Sanofi SA
14.3. Pharming Healthcare
Inc.
14.4. Attune
Pharmaceuticals
14.5. Adverum
Biotechnologies
14.6. Arrowhead
Pharmaceuticals
14.7. Ionis
Pharmaceuticals
14.8. BioCryst
Pharmaceuticals Inc.
14.9. CSL Behring.
14.10.
CENTOGENE N.V.
15. Strategic Recommendations
16. About Us & Disclaimer